Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

Cancer Cell

Volumn 15, Issue 3, 2009, Pages 220-231

  Pàez Ribes, Marta ^a   Allen, Elizabeth ^b   Hudock, James ^c   Takeda, Takaaki ^d   Okuyama, Hiroaki ^d   Viñals, Francesc ^a,e   Inoue, Masahiro ^d   Bergers, Gabriele ^c   Hanahan, Douglas ^b   Casanovas, Oriol ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^e UNIVERSITY OF BARCELONA   (Spain)

Author keywords

CELLCYCLE

Indexed keywords

SUNITINIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; GENE DELETION; GLIOBLASTOMA; LIVER METASTASIS; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL;

EID: 60649106195     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2009.01.027     Document Type: Article

References (45)

1. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., Kozak K.R., Cahill D.P., Chen P.J., Zhu M., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (2007) 83-95
2. Bendell J.C., Domchek S.M., Burstein H.J., Harris L., Younger J., Kuter I., Bunnell C., Rue M., Gelman R., and Winer E. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97 (2003) 2972-2977
3. Berger M.S., and Wilson C.B. The Gliomas (1999), W.B. Saunders Company, Philadelphia
4. Bergers G., and Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8 (2008) 592-603
5. Bergers G., Song S., Meyer-Morse N., Bergsland E., and Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111 (2003) 1287-1295
6. Blouw B., Song H., Tihan T., Bosze J., Ferrara N., Gerber H.P., Johnson R.S., and Bergers G. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4 (2003) 133-146
7. Blouw B., Haase V.H., Song H., Bergers G., and Johnson R.S. Loss of vascular endothelial growth factor expression reduces vascularization, but not growth, of tumors lacking the Von Hippel-Lindau tumor suppressor gene. Oncogene 26 (2007) 4531-4540
8. Cairns R.A., Kalliomaki T., and Hill R.P. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res. 61 (2001) 8903-8908
9. Casanovas O., Hicklin D.J., Bergers G., and Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8 (2005) 299-309
10. Clayton A.J., Danson S., Jolly S., Ryder W.D., Burt P.A., Stewart A.L., Wilkinson P.M., Welch R.S., Magee B., Wilson G., et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br. J. Cancer 91 (2004) 639-643
11. Du R., Lu K.V., Petritsch C., Liu P., Ganss R., Passegue E., Song H., Vandenberg S., Johnson R.S., Werb Z., and Bergers G. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13 (2008) 206-220
12. Ebos J.M.L., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., and Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15 (2009) 232-239 this issue
13. Faivre S., Demetri G., Sargent W., and Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 6 (2007) 734-745
14. Fischer I., Cunliffe C., Bollo R., Raza S., Monoky D., Chiriboga L., Parker E., Golfinos J., Kelly P., Knopp E., et al. High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neuro-oncol. 10 (2008) 700-708
15. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
16. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov. 6 (2007) 273-286
17. Folkman J., and Ingber D. Inhibition of angiogenesis. Semin. Cancer Biol. 3 (1992) 89-96
18. Gomez-Manzano C., Holash J., Fueyo J., Xu J., Conrad C.A., Aldape K.D., de Groot J.F., Bekele B.N., and Yung W.K. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol. 10 (2008) 940-945
19. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315 (1985) 115-122
20. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
21. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
22. Higgins D.F., Kimura K., Bernhardt W.M., Shrimanker N., Akai Y., Hohenstein B., Saito Y., Johnson R.S., Kretzler M., Cohen C.D., et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J. Clin. Invest. 117 (2007) 3810-3820
23. Inoue M., Hager J.H., Ferrara N., Gerber H.P., and Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1 (2002) 193-202
24. Kerbel R.S. Tumor angiogenesis: past, present and the near future. Carcinogenesis 21 (2000) 505-515
25. Kerbel R.S., Yu J., Tran J., Man S., Viloria-Petit A., Klement G., Coomber B.L., and Rak J. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 20 (2001) 79-86
26. Kunkel P., Ulbricht U., Bohlen P., Brockmann M.A., Fillbrandt R., Stavrou D., Westphal M., and Lamszus K. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 61 (2001) 6624-6628
27. Lopez T., and Hanahan D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 1 (2002) 339-353
28. Miller K.D., Weathers T., Haney L.G., Timmerman R., Dickler M., Shen J., and Sledge Jr. G.W. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann. Oncol. 14 (2003) 1072-1077
29. Miller K.D., Sweeney C.J., and Sledge Jr. G.W. Can tumor angiogenesis be inhibited without resistance?. EXS 94 (2005) 95-112
30. Munoz-Najar U.M., Neurath K.M., Vumbaca F., and Claffey K.P. Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene 25 (2006) 2379-2392
31. Narayana A., Kelly P., Golfinos J., Parker E., Johnson G., Knopp E., Zagzag D., Fischer I., Raza S., Medabalmi P., et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J. Neurosurg. 110 (2009) 173-180
32. Norden A.D., Young G.S., Setayesh K., Muzikansky A., Klufas R., Ross G.L., Ciampa A.S., Ebbeling L.G., Levy B., Drappatz J., et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70 (2008) 779-787
33. Offerhaus G.J., Giardiello F.M., Bruijn J.A., Stijnen T., Molyvas E.N., and Fleuren G.J. The value of immunohistochemistry for collagen IV expression in colorectal carcinomas. Cancer 67 (1991) 99-105
34. Parangi S., O'Reilly M., Christofori G., Holmgren L., Grosfeld J., Folkman J., and Hanahan D. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl. Acad. Sci. USA 93 (1996) 2002-2007
35. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., and Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3 (2003) 347-361
36. Pietras K., and Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol. 23 (2005) 939-952
37. Roskoski Jr. R. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem. Biophys. Res. Commun. 356 (2007) 323-328
38. Rubenstein J.L., Kim J., Ozawa T., Zhang M., Westphal M., Deen D.F., and Shuman M.A. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2 (2000) 306-314
39. Shaked Y., Bertolini F., Man S., Rogers M.S., Cervi D., Foutz T., Rawn K., Voskas D., Dumont D.J., Ben-David Y., et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7 (2005) 101-111
40. Skobe M., Rockwell P., Goldstein N., Vosseler S., and Fusenig N.E. Halting angiogenesis suppresses carcinoma cell invasion. Nat. Med. 3 (1997) 1222-1227
41. Waggoner S.E. Cervical cancer. Lancet 361 (2003) 2217-2225
42. Warren R.S., Yuan H., Matli M.R., Gillett N.A., and Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95 (1995) 1789-1797
43. Weil R.J., Palmieri D.C., Bronder J.L., Stark A.M., and Steeg P.S. Breast cancer metastasis to the central nervous system. Am. J. Pathol. 167 (2005) 913-920
44. Xian X., Hakansson J., Stahlberg A., Lindblom P., Betsholtz C., Gerhardt H., and Semb H. Pericytes limit tumor cell metastasis. J. Clin. Invest. 116 (2006) 642-651
45. Young S.D., and Hill R.P. Effects of reoxygenation on cells from hypoxic regions of solid tumors: anticancer drug sensitivity and metastatic potential. J. Natl. Cancer Inst. 82 (1990) 371-380